Overview
Fibrinogen is a key blood protein that helps form clots and stop bleeding. In most settings, low fibrinogen levels, known as hypofibrinogenemia, reduce clot formation. However, whether this also lowers the risk of arterial thrombosis, such as clots in the carotid or coronary arteries, has been unclear. This study examines how low fibrinogen levels and a specific part of the fibrinogen molecule, called the αC region, influence arterial clot formation.
Why this study matters
Arterial thrombosis is a major cause of heart attack and stroke. It usually develops on top of a damaged or inflamed vessel wall, where platelets, fibrin, and other clotting factors work together to form a plug. Because fibrinogen is central to this process, researchers have long expected that reducing fibrinogen might protect against dangerous clots. But blood clotting is more complex than simply lowering the amount of fibrinogen. The structure of fibrinogen also appears to matter, especially the αC region, which may affect how fibrin interacts with platelets and how stable a clot becomes.
What the researchers found in patients
The investigators reviewed a cohort of 264 patients with congenital fibrinogen disorders. Among them, 19 patients, or about 7%, experienced arterial thrombosis. In the subgroup with hypofibrinogenemia, 4 of 41 patients, or about 10%, had arterial thrombosis. This finding is important because it shows that low fibrinogen does not automatically prevent arterial clotting in humans.
A different pattern emerged in patients with fibrinogen αC-region truncation mutations. None of the 8 patients in this group reported arterial thrombosis during 286 patient-years of follow-up. This observation suggested that the αC region may play a special role in promoting arterial clot formation, beyond the effect of fibrinogen concentration alone.
Mouse models used to test the mechanism
To explore this question more directly, the researchers studied two mouse models. The first model involved wild-type mice treated with lipid nanoparticles carrying small interfering RNA against fibrinogen, called siFga. This treatment lowered fibrinogen levels and created a hypofibrinogenemic state. The second model, Fga270/270 mice, produced fibrinogen with a truncated αC region, allowing the team to isolate the effect of losing this structural domain.
The scientists then induced carotid artery injury using ferric chloride (FeCl3), a standard experimental method for triggering arterial thrombosis. In this model, a clot forms in the injured artery, and researchers can observe how quickly and how completely the vessel becomes blocked.
Main experimental results
The two mouse models produced different outcomes. Mice with reduced fibrinogen levels because of siFga treatment still developed occlusive carotid thrombi, similar to control mice. In other words, low fibrinogen alone did not protect them from arterial thrombosis in this experimental setting.
By contrast, Fga270/270 mice, which lacked the fibrinogen αC region, showed markedly reduced carotid thrombosis after FeCl3 injury. This suggests that the αC region, rather than fibrinogen quantity by itself, is an important driver of arterial clot formation.
The researchers concluded that loss of the αC region impairs arterial thrombosis more strongly than hypofibrinogenemia alone. This finding helps explain why patients with truncation mutations in the αC region may have less arterial thrombotic risk than patients with low fibrinogen levels but otherwise intact fibrinogen structure.
The role of platelets and GPVI
Platelets are central to arterial thrombosis because they respond rapidly to vessel injury and to exposed collagen in the damaged artery wall. One important platelet receptor is glycoprotein VI, or GPVI, which binds collagen and helps activate platelets. Previous work has suggested that fibrinogen and fibrin may also interact with platelets in ways that strengthen clot growth.
To determine whether protection from thrombosis in Fga270/270 mice was related to reduced interaction between the αC region and platelet GPVI, the researchers depleted platelet GPVI using an antibody called JAQ1. This antibody is commonly used in mouse studies to functionally remove GPVI from platelets and test its role in clotting.
In wild-type mice, JAQ1 treatment reduced arterial thrombosis after a mild FeCl3 injury using 5% FeCl3, but not after a stronger 10% FeCl3 injury. This indicates that GPVI contributes to thrombosis, especially when the vascular injury is less severe. Under stronger injury conditions, other clotting pathways may compensate.
Interestingly, JAQ1 also suppressed arterial thrombosis in siFga-treated mice. However, in Fga270/270 mice, JAQ1 did not further improve protection after the more severe 10% FeCl3 challenge. This suggests that the antithrombotic benefit from αC-region truncation may overlap with the pathway mediated by GPVI. In other words, once the αC region is missing, blocking GPVI may not add much additional protection.
Interpretation of the findings
Together, these results support a new view of fibrinogen biology. The amount of fibrinogen is important, but its structure also matters. The αC region appears to promote arterial thrombosis in hypofibrinogenemic conditions, likely by supporting platelet-fibrin interactions and clot stability.
This has clinical relevance because patients with congenital fibrinogen disorders do not all have the same thrombotic risk. Some patients with low fibrinogen may still develop arterial clots, while others with specific structural mutations may be relatively protected. Understanding these differences could eventually help guide individualized risk assessment and management.
Clinical implications
At present, these findings do not change routine treatment recommendations for patients with fibrinogen disorders, but they do point toward a more refined understanding of clot risk. Clinicians already know that bleeding and thrombosis can coexist in fibrinogen disorders, and treatment decisions must balance both risks carefully.
Potential implications include improved genetic risk stratification, better prediction of who may need antithrombotic therapy, and the possibility of targeting fibrinogen-platelet interactions more selectively in the future. However, this remains preclinical and observational work. Larger studies in patients, together with additional mechanistic experiments, will be needed before translating these insights into practice.
Limitations
As with all studies, there are limitations. The patient cohort with αC-region truncation mutations was small, so the absence of arterial thrombosis in that group should be interpreted cautiously. The animal models also represent controlled experimental systems that cannot fully reproduce the complexity of human arterial disease, which is influenced by age, atherosclerosis, diabetes, smoking, cholesterol, and medications.
In addition, the FeCl3 model measures thrombosis after an artificial vessel injury, which may not exactly mimic spontaneous clot formation in human arteries. Even so, the consistency between human genetic observations and mouse experiments makes the findings compelling.
Conclusion
This study shows that low fibrinogen alone does not necessarily prevent arterial thrombosis. Instead, the fibrinogen αC region appears to be a key structural element that promotes arterial clot formation in hypofibrinogenemic states. By linking patient data with mechanistic mouse studies, the authors provide evidence that fibrinogen structure, not just fibrinogen level, helps determine thrombotic risk. This work may open the door to more precise approaches for understanding and eventually managing thrombosis in patients with inherited fibrinogen disorders.